Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer.

ABSTRACT: There is increasing interest in the use of cell-free circulating tumor DNA (ctDNA) as a serum marker for therapy assessment in prostate cancer patients. Prostate cancer is characterized by relatively low numbers of mutations, and, in contrast to many other common epithelial cancers, commercially available single nucleotide mutation assays for quantification of ctDNA are insufficient for therapy assessment in this disease. However, prostate cancer shares some similarity with translocation-affected mesenchymal tumors (e.g., leukemia and Ewing sarcoma), which are common in pediatric oncology, where chromosomal translocations are used as biomarkers for quantification of the tumor burden. Approximately 50% of prostate cancers carry a chromosomal translocation resulting in generation of the TMPR

SUBMITTER: Krumbholz M 

PROVIDER: S-EPMC6930771 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature